Case reportPublished 16 Aug 2019
Erlotinib Induced Trichomegaly-Case Report and Literature Review
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Lung cancer is a leading cause of cancer-associated mortality worldwide. Targeted therapy has been developed and is widely used for the treatment of Non-Small Cell Lung Cancer (NSCLC), particularly in patients harboring an activating Epidermal Growth Factor Receptor (EGFR) mutation. Erlotinib is a Tyrosine Kinase Inhibitor (TKI) used in the treatment of advanced Non-Small Cell Lung cancer (NSCLC) which harbors the Epidermal Growth Factor Receptor (EGFR) mutation. Impressive responses have been seen after the introduction of this molecule and it is currently the standard of care in patients with EGFR mutations. Common side effects include skin rash, mucositis, and diarrhoea. Recent reports demonstrate that medications that act on the Epithelial Growth Factor Receptor (EGFR) may induce trichomegaly. Erlotinib induced Trichomegaly is a relatively rare and peculiar side effect of this drug. Here we report a case of advanced NSCLC on Erlotinib with trichomegaly and literature review.
Subjects
DermatologyAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalDermatology Case Reports
- SubjectDermatology
- BylineArticles whose byline prints “Kalpathi Krishnamani”
- BylineArticles whose byline prints “Lingutla Arun Kumar”
- BylineArticles whose byline prints “Ranjit Kumar CS”
- BylineArticles whose byline prints “Aribandi Harshita”
- BylineArticles whose byline prints “Jabeen Nazia”
